Home Featured Page 197

Featured

Latest

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor...

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive...

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase...

PT286 – Joe Tafur, MD – Vital Psychedelic Conversations

Psychedelic Company Highlights in 2021

Psychedelic Science Leader Eleusis to Become Public Company in Merger with...

Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical...

Awakn Life Sciences Signs MOU with Maps

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit...

Psygen Receives Dealer’s Licence from Health Canada

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor...

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive...

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase...

PT286 – Joe Tafur, MD – Vital Psychedelic Conversations

Psychedelic Company Highlights in 2021

Psychedelic Science Leader Eleusis to Become Public Company in Merger with...

Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical...

Awakn Life Sciences Signs MOU with Maps

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit...

Psygen Receives Dealer’s Licence from Health Canada

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY